rs113488022
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The present case is the first pediatric case showing BRAF V600E-mutated intracerebral histiocytic sarcoma.
|
28748542 |
2017 |
rs121913377
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The present case is the first pediatric case showing BRAF V600E-mutated intracerebral histiocytic sarcoma.
|
28748542 |
2017 |
rs113488022
|
|
|
0.020 |
GeneticVariation |
BEFREE |
BRAF(V600E) was not limited to LCH and was detected more frequently in histiocytic sarcoma.
|
24720374 |
2014 |
rs121913377
|
|
|
0.020 |
GeneticVariation |
BEFREE |
BRAF(V600E) was not limited to LCH and was detected more frequently in histiocytic sarcoma.
|
24720374 |
2014 |
rs121913338
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Next-generation sequencing and whole-exome sequencing (WES) studies detected 35 common mutations, as well as mutations unique to B-ALL (16) and HS (15), including BRAF D594G.
|
31172191 |
2019 |
rs121913496
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We have now identified a second missense mutation in PTPN11 (G503V), and a mutation in KRAS (Q61H) present in HS cell lines.
|
31277422 |
2019 |
rs17851045
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We have now identified a second missense mutation in PTPN11 (G503V), and a mutation in KRAS (Q61H) present in HS cell lines.
|
31277422 |
2019 |
rs397507546
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We have now identified a second missense mutation in PTPN11 (G503V), and a mutation in KRAS (Q61H) present in HS cell lines.
|
31277422 |
2019 |
rs121913341
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We investigated an atypical BRAF mutation, F595L, which was identified along with mutant HRAS in histiocytic sarcoma and also occurs in epithelial cancers, melanoma and neuroblastoma, and determined its interaction with mutant RAS.
|
26582644 |
2016 |
rs794729219
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We investigated an atypical BRAF mutation, F595L, which was identified along with mutant HRAS in histiocytic sarcoma and also occurs in epithelial cancers, melanoma and neuroblastoma, and determined its interaction with mutant RAS.
|
26582644 |
2016 |